Perspectives in biomarker research in prostate cancer
Poster Session 82
Monday 20 July 15:45 - 17:15
Location: Green Area, Room 5
Chairs: To be confirmed
H. Erb, Dresden (DE)
H. Klocker, Inzing (AT)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

* 1122

CDK12 expression profile and correlation with tumor associated immune cell infiltrates in prostate cancer

By: Hupe M.C. 1, Offermann A. 2, Schreiber C. 2, Merseburger A.S. 1, Perner S. 3
1 University Hospital Schleswig-Holstein, Campus Luebeck, Dept. of Urology, Lübeck, Germany, 2 University Hospital Schleswig-Holstein, Campus Luebeck, Institute of Pathology, Lübeck, Germany, 3 University Hospital Schleswig-Holstein and Research Center Borstel, Leibniz Lung Center, Institute of Pathology, Lübeck, Germany

* 1123

Contrasting genomic profiles in post-systemic treatment metastatic sites (MET) and pre-treatment primary tumors (PT) of clinically advanced prostate cancer (PC)

1 Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, 2 University of Washington, Seattle Cancer Care Alliance, Dept. of Medical Oncology, Seattle, United States of America, 3 Upstate University, Dept. of Urology, New York, United States of America, 4 Foundation Medicine, Cambridge, United States of America

* 1124

Identification of the prostate cancer exosome surface proteome and its application to detect prostate cancer in urine
To be confirmed

1125

Biomarker accompanied significance of mpMRI-visible and invisible lesions for adverse pathology and biochemical recurrence after radical prostatectomy

By: Eineluoto J. 1, Sandeman K 1, Pohjonen J 1, Sopyllo K. 1, Nordling S. 2, Stürenberg C. 1, Pellinen T. 3, Matikainen M. 4, Petas A. 4, Santti H. 4, Kilpeläinen T. 4, Järvinen P. 4, Rannikko A.S. 4, Mirtti T. 1
1 University of Helsinki, Research Program in Systems Oncology, Helsinki, Finland, 2 University of Helsinki, Dept. of Pathology, Helsinki, Finland, 3 University of Helsinki, Institute for Molecular Medicine, Helsinki, Finland, 4 HUS Helsinki University Hospital, Dept. of Urology, Helsinki, Finland
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Abstract</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1126</td>
<td>Genomic analysis of localized prostate cancer identifies AZIN1 as driver of metastatic progression</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>1127</td>
<td>Utility of circulating tumor DNA methylation biomarkers in newly diagnosed prostate cancer</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>1128</td>
<td>Prognostic value of germline DNA repair gene mutations in de novo metastatic and treatment-naive prostate cancer</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>1129</td>
<td>Novel 3D cell culture model for discovery of cancer-specific extracellular vesicles based biomarkers and clinical validation in patient plasma</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>1130</td>
<td>Withdrawn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1131</td>
<td>Studies on liquid biopsies of CP/CPPS patients reveal epigenetic dysregulation of tumor suppressor genes and suggest a risk for prostate cancer</td>
<td>To be confirmed</td>
<td></td>
</tr>
<tr>
<td>1132</td>
<td>mpMRI-visible prostate cancer is enriched with genomic hallmarks of poor prognosis: A bioinformatic analysis</td>
<td>To be confirmed</td>
<td></td>
</tr>
</tbody>
</table>

**16:58 - 17:05**

**Summary**

H. Erb, Dresden (DE)